News
07-31-2018, 08:20 AM
Pfizer Inc. today announced the European Commission has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
More... (https://www.news-medical.net/news/20180731/European-Commission-approves-Pfizere28099s-first-oncology-biosimilar.aspx)
More... (https://www.news-medical.net/news/20180731/European-Commission-approves-Pfizere28099s-first-oncology-biosimilar.aspx)